City briefs: Kromek; ProBiotix Health; and more
Kromek, a developer of radiation and bio-detection technology solutions, has been awarded a contract worth £2m by the UK Ministry of Defence for the supply of nuclear radiation detectors and ancillary products.
The contract is to be delivered in the Huddersfield-based group’s current financial year ending 30 April 2025.
The contract, which was awarded after a competitive tender process, is for the supply of the group’s D5 RIID, a handheld, highly-sensitive gamma and neutron detector, along with the group’s Alpha Beta probe attachment and other associated products.
Launched in November 2023, the Alpha Beta probe connects directly to the D5 RIID to enable alpha and beta radiation to be detected, allowing the single, small form factor upgraded device to detect all types of radioactive material.
Arnab Basu, CEO of Kromek, said: “We are pleased to have won this important contract from the UK MOD, which is a significant strategic customer for Kromek.
“That it was awarded after a rigorous tender process provides excellent endorsement of the strength of our solution.
“It is also great validation to receive this key order for our Alpha Beta probe so soon after its launch at the end of last year.
“With the Alpha Beta probe upgrade, our D5 RIID is one of the most versatile handheld radiation detectors available today.
“We are looking forward to delivering this contract and supporting UK national defence efforts and to continuing to strengthen our relationship with this important customer.”
:::
ProBiotix Health, a life sciences business developing probiotics to support cardiometabolic health, has entered a commercial partnership with Greece-based consumer brands specialist, Eifron SA.
As part of the deal, Eifron will introduce YourBiotixBP tablets, containing ProBiotix’s product LPLDL®, under its existing probiotic consumer brand, with the anticipated product launch expected to be in quarter one 2025.
Through this partnership, Eifron will expand its own portfolio by including a product for cholesterol and blood pressure lowering based on LPLDL®.
The addition of other products from the ProBiotix portfolio will be evaluated by the parties on an ongoing basis.
ProBiotix Health has received a purchase order from Eifron, with the first sales planned for Greece and afterwards in selected regions in Europe.
Founded in 2011, Eifron specialises in healthcare solutions. In Greece it is among the top five brands in the country.
Its core focus is addressing unmet medical needs by developing and distributing advanced product solutions for the health sector, with particularly close ties among pharmacies and healthcare professionals. The current Eifron product portfolio includes pharmaceuticals, supplements, and medical devices.
Steen Andersen, CEO of Wakefield-based ProBiotix, said: “This exceptional opportunity to work with a science driven market leader like Eifron represents another significant milestone in our efforts to expand our reach and broaden the availability of our innovative cardiometabolic health product solutions in Europe.
“Eifron’s reputation and expertise in the health sector and their commitment to natural solutions makes them an ideal partner for us.”
Elias Kartasiadis, CEO of Eifron, added: “We are thrilled to partner with ProBiotix Health and bring their scientifically-backed products to our markets.
“This partnership aligns perfectly with our mission to provide our customers with effective and natural health solutions.
“We believe this collaboration will help us expand our reach and offer differentiation and added value to the growing group of consumers looking to improve their cardiometabolic health.”
:::
IntelliAM AI, a Sheffield-based software business which uses the power of AI and machine learning to support the manufacturing industry, has won contracts with Hovis for its consultancy reliability services.
This includes contracts for three large Hovis sites in East London, Nottingham and Glasgow, and project services for all Hovis manufacturing sites.
The services will be linked to the IntelliAM AI platform to support reliability and stability in the operation.
These service and project orders will be worth more than £100,000 over a 12-month period, starting next month.
Hovis is part of the private equity firm Endless LLP.
